Miranda B. Olson, MSc, Stacey Springs, PhD, and Jay Baruch, MD
Responsible arts in health research requires interrogating what counts as evidence, especially when the insistence on rigor risks oversimplifying and diminishing what’s ineffable about the arts.
AMA J Ethics. 2022;24(7):E617-621. doi:
10.1001/amajethics.2022.617.
Sofie Layton, MRes, Jo Wray, PhD, Victoria Walsh, PhD, and Giovanni Biglino, PhD
Based on an artist’s, bioengineer’s, and health psychologist’s reflections on pediatric and adult group workshop practice settings, this article suggests 8 dimensions of risk that deserve ethical attention.
AMA J Ethics. 2022;24(7):E638-645. doi:
10.1001/amajethics.2022.638.
Dr Ala Shaikhkhalil joins Ethics Talk to discuss her article, coauthored with Drs Ethan A. Mezoff and Hannah Hays: “Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D?”
Dr David J. Satin joins Ethics Talk to discuss his article, coauthored with Drs Christine C. Danner and Ila M. Harris: “How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements?”
Health system function, resilience, and sustainability are needed to help prepare trainees to lead, innovate, and prioritize a circular supply chain with low emissions.
AMA J Ethics. 2022;24(10):E951-958. doi:
10.1001/amajethics.2022.951.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”
Sarosh Nagar joins Ethics Talk to discuss his article, coauthored with Drs Leah Z. Rand and Aaron S. Kesselheim: “What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?”